John Mohr
Directeur Technique/Scientifique/R&D chez SCPHARMACEUTICALS INC.
Postes actifs de John Mohr
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SCPHARMACEUTICALS INC. | Directeur Technique/Scientifique/R&D | 01/05/2018 | - |
Historique de carrière de John Mohr
Anciens postes connus de John Mohr
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| TETRAPHASE PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/07/2015 | 01/05/2016 |
| THE MEDICINES COMPANY | Directeur Technique/Scientifique/R&D | 01/03/2015 | 01/06/2015 |
| The University of Texas Medical School At Houston | Corporate Officer/Principal | 01/01/2003 | 01/10/2007 |
Formation de John Mohr
| Texas A&M University | Undergraduate Degree |
| University of Houston | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 7 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SCPHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
